Barclays Issues Pessimistic Forecast for Allegion (NYSE:ALLE) Stock Price

Allegion (NYSE:ALLE) had its target price lowered by investment analysts at Barclays from $176.00 to $165.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the scientific and technical instruments company’s stock. Barclays‘s target price would suggest a potential upside of 14.42% from the stock’s current price.

Several other research firms also recently issued reports on ALLE. JPMorgan Chase & Co. lowered their price objective on Allegion from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 18th. Weiss Ratings reissued a “buy (b)” rating on shares of Allegion in a report on Wednesday, January 21st. Finally, Wells Fargo & Company decreased their price target on shares of Allegion from $175.00 to $155.00 and set an “equal weight” rating for the company in a research report on Wednesday. Three research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $171.13.

Allegion Price Performance

Shares of NYSE ALLE traded down $1.09 during mid-day trading on Wednesday, hitting $144.20. 370,888 shares of the stock traded hands, compared to its average volume of 895,357. The company has a market cap of $12.42 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 3.09 and a beta of 1.03. Allegion has a twelve month low of $116.57 and a twelve month high of $183.11. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.84 and a quick ratio of 1.16. The firm has a 50 day simple moving average of $159.22 and a two-hundred day simple moving average of $164.41.

Allegion (NYSE:ALLE) last issued its earnings results on Tuesday, February 17th. The scientific and technical instruments company reported $1.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.01 by ($0.07). Allegion had a return on equity of 38.06% and a net margin of 15.83%.The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the previous year, the company earned $1.86 EPS. Allegion’s revenue for the quarter was up 9.3% on a year-over-year basis. Allegion has set its FY 2026 guidance at 8.700-8.900 EPS. As a group, equities research analysts forecast that Allegion will post 7.77 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Sue Main purchased 2,000 shares of the stock in a transaction on Wednesday, March 11th. The stock was purchased at an average price of $149.61 per share, for a total transaction of $299,220.00. Following the acquisition, the director owned 2,000 shares in the company, valued at $299,220. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven Mizell sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $161.51, for a total transaction of $161,510.00. Following the completion of the transaction, the director owned 4,915 shares in the company, valued at $793,821.65. This trade represents a 16.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.23% of the stock is owned by insiders.

Hedge Funds Weigh In On Allegion

A number of hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Allegion by 7.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,592 shares of the scientific and technical instruments company’s stock valued at $1,251,000 after acquiring an additional 626 shares during the last quarter. NewEdge Advisors LLC grew its stake in Allegion by 35.3% during the first quarter. NewEdge Advisors LLC now owns 3,272 shares of the scientific and technical instruments company’s stock worth $427,000 after purchasing an additional 854 shares during the period. Jones Financial Companies Lllp increased its holdings in Allegion by 44.2% in the first quarter. Jones Financial Companies Lllp now owns 1,629 shares of the scientific and technical instruments company’s stock worth $213,000 after purchasing an additional 499 shares in the last quarter. Empowered Funds LLC lifted its stake in Allegion by 13.0% in the first quarter. Empowered Funds LLC now owns 5,673 shares of the scientific and technical instruments company’s stock valued at $740,000 after buying an additional 651 shares during the period. Finally, Focus Partners Wealth lifted its stake in Allegion by 204.5% in the first quarter. Focus Partners Wealth now owns 7,186 shares of the scientific and technical instruments company’s stock valued at $937,000 after buying an additional 4,826 shares during the period. Institutional investors own 92.21% of the company’s stock.

About Allegion

Allegion plc (NYSE: ALLE) is a global provider of security products and solutions focused on ensuring the safety and security of people and property. The company was formed in December 2013 through a corporate spin-off from Ingersoll Rand and is head­quartered in Dublin, Ireland. Allegion’s core mission is to deliver innovative mechanical and electronic access control systems for a wide range of end markets, including commercial buildings, residential properties, institutional facilities, and industrial sites.

The company’s product portfolio spans mechanical locksets, door closers, exit devices, key systems and cylinders, as well as a growing suite of electronic and smart access control offerings.